NasdaqGM - Nasdaq Real Time Price • USD
Aurinia Pharmaceuticals Inc. (AUPH)
As of 9:35 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 6 |
Avg. Estimate | -0.14 | -0.02 | -0.05 | 0.39 |
Low Estimate | -0.2 | -0.06 | -0.34 | -0.14 |
High Estimate | 0.01 | 0.04 | 0.15 | 0.83 |
Year Ago EPS | -0.18 | -0.08 | -0.54 | -0.05 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 6 |
Avg. Estimate | 47.45M | 53.44M | 224.25M | 288.87M |
Low Estimate | 46M | 49M | 207M | 250M |
High Estimate | 51.82M | 56.31M | 232.83M | 339.89M |
Year Ago Sales | 34.41M | -- | 175.51M | 224.25M |
Sales Growth (year/est) | 37.90% | -- | 27.80% | 28.80% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.22 | -0.18 | -0.17 | -0.16 |
EPS Actual | -0.18 | -0.08 | -0.09 | -0.19 |
Difference | 0.04 | 0.1 | 0.08 | -0.03 |
Surprise % | 18.20% | 55.60% | 47.10% | -18.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.14 | -0.02 | -0.05 | 0.39 |
7 Days Ago | -0.14 | -0.02 | -0.05 | 0.39 |
30 Days Ago | -0.14 | -0.02 | -0.05 | 0.39 |
60 Days Ago | -0.13 | -0.02 | -0.05 | 0.4 |
90 Days Ago | -0.13 | -0.08 | -0.35 | -0.02 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | AUPH | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 22.20% | -- | -- | 1.50% |
Next Qtr. | 75.00% | -- | -- | 12.10% |
Current Year | 90.70% | -- | -- | 4.40% |
Next Year | 880.00% | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
Maintains | Cantor Fitzgerald: Overweight to Overweight | 2/23/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 2/22/2024 |
Maintains | RBC Capital: Outperform to Outperform | 2/16/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 9/22/2023 |
Maintains | HC Wainwright& Co.: Buy to Buy | 8/7/2023 |
Related Tickers
TGTX TG Therapeutics, Inc.
13.71
-1.44%
BCRX BioCryst Pharmaceuticals, Inc.
4.1200
-0.96%
HEPA Hepion Pharmaceuticals, Inc.
1.2834
-0.52%
AXSM Axsome Therapeutics, Inc.
69.97
-2.17%
MDGL Madrigal Pharmaceuticals, Inc.
189.99
-2.27%
ARDX Ardelyx, Inc.
6.33
+0.24%
MCRB Seres Therapeutics, Inc.
0.7428
+0.01%
DAWN Day One Biopharmaceuticals, Inc.
13.65
+3.29%
AMLX Amylyx Pharmaceuticals, Inc.
1.8050
+1.40%
OCUL Ocular Therapeutix, Inc.
4.1000
-2.38%